Ocular Therapeutix (NASDAQ:OCUL) Insider Namrata Saroj Sells 35,370 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Namrata Saroj sold 35,370 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $6.55, for a total value of $231,673.50. Following the completion of the sale, the insider owned 220,522 shares in the company, valued at approximately $1,444,419.10. This represents a 13.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Up 3.9%

NASDAQ:OCUL opened at $6.85 on Tuesday. Ocular Therapeutix, Inc. has a 52 week low of $6.00 and a 52 week high of $16.44. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. The stock’s 50-day moving average price is $8.33 and its 200-day moving average price is $9.00.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. The company had revenue of $12.87 million for the quarter, compared to analyst estimates of $14.27 million. During the same quarter in the prior year, the company posted ($0.38) earnings per share. The business’s revenue was down 11.5% on a year-over-year basis. Sell-side analysts predict that Ocular Therapeutix, Inc. will post -1.47 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, October 20th. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Finally, UBS Group initiated coverage on shares of Ocular Therapeutix in a research note on Sunday, October 11th. They issued a “buy” rating and a $14.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Ocular Therapeutix said it plans to submit an AXPAXLI NDA in the fourth quarter of 2026. The company reported $530.6 million in cash, which it expects to fund operations into 2028, helping ease near-term financing concerns. Article: AXPAXLI NDA plan and cash runway
• Neutral Sentiment: The company appointed Riad Sherif to its board of directors, a governance update without an immediately clear financial impact. Article: Board appointment
• Neutral Sentiment: Insider Namrata Saroj sold 35,370 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated reason and existing plan make the sale less indicative of a discretionary view on the stock. SEC insider transaction filing
• Negative Sentiment: Third-quarter adjusted loss was $0.42 per share, worse than the $0.36 loss analysts expected; revenue of $12.87 million also missed the $14.27 million consensus and fell 11.5% year over year. The earnings shortfall and weaker sales contributed to pressure on OCUL shares. Article: Ocular Therapeutix falls on third-quarter earnings miss
• Negative Sentiment: Coverage also highlighted costs associated with advancing AXPAXLI and declining DEXTENZA sales, raising questions about near-term operating performance as the company pursues its pipeline. Article: Q3 results, pipeline costs, and DEXTENZA

Institutional Trading of Ocular Therapeutix

A number of institutional investors and hedge funds have recently bought and sold shares of OCUL. Rockefeller Capital Management L.P. purchased a new stake in Ocular Therapeutix during the 4th quarter worth approximately $31,000. Integrated Wealth Concepts LLC acquired a new stake in Ocular Therapeutix during the 2nd quarter worth approximately $51,000. Sterling Capital Management LLC boosted its position in Ocular Therapeutix by 401.7% in the 3rd quarter. Sterling Capital Management LLC now owns 6,612 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 5,294 shares during the period. Root Financial Partners LLC purchased a new position in Ocular Therapeutix in the 3rd quarter valued at approximately $66,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Ocular Therapeutix in the 3rd quarter valued at approximately $86,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.

Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

The company was founded in 2006 and serves the U.S.